Skip to content

Disposable Energy Sources and Operating Room Time for Laparoscopic Hysterectomy

Disposable Energy Sources and Operating Room Time for Laparoscopic Hysterectomy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02065453
Enrollment
52
Registered
2014-02-19
Start date
2012-01-31
Completion date
2014-01-31
Last updated
2017-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign Uterine Disease

Keywords

lap hysterectomy, Women in need of a lap hysterectomy for benign disease.

Brief summary

Over 600,000 hysterectomies are performed each year nationwide. Over 99% of these are accomplished laparoscopically in the investigators current surgical practice to allow women a quicker recovery than a traditional large incision. Disposable laparoscopic devices have been developed to assist in the completion of hysterectomies. These disposable energy sources are only used once, but offer an improved safety and energy profile in that they reliably control bleeding with little damage to surrounding tissue and potentially save time. Reusable energy instruments can be sterilized and reused for multiple cases. Operating room time is expensive. The investigators calculate that if 6.7 minutes of time can be saved using the disposable device, Ligasure (Covidien), versus the reusable Robi bipolar and Storz Laparoscopic Shears, the time savings could justify the cost of the device.

Detailed description

This will be a randomized, prospective study. The investigators study design would have each patient serve as their own control. One side of the uterine attachments would be transected using the disposable device, Ligasure (Covidien), and the other using the two reusable devices (Robi bipolar and Storz laparoscopic shears). It is the investigators standard practice that the attending surgeon is on the patient's left side while the resident physician is on the patients right. To eliminate the bias of surgical experience, the investigators will randomize the energy source used on each side for every case. Therefore, the number of cases performed by the attending surgeon with the disposable or reusable energy sources, will equal that of the less experienced resident surgeon. The primary endpoint of this study would be the time difference between cauterizing one side of the uterine attachments, from the round ligament to the uterine artery on one side, to the time detaching the same tissues on the other side. The vesico-uterine peritoneum or bladder flap, will always be transected from the left for consistency. Sealed, opaque envelopes will be randomized to determine which side of the uterus will get the single disposable instrument, and which will get the 2 reusable instruments. A time savings of 6.7 minutes for the total case can also be explained by a 3.35 minute time savings PER SIDE of the uterine attachments, given each uterus has two sides. There is no pre-existing data on time needed for coagulation and cutting of the vascular tissues. Based on experience, the investigators estimate that it takes on average about 20 min total time for vessel sealing, with an estimated variability that approximately 70% of the time, vessel sealing is done within 35 minutes. Given these estimates, and using a power of 0.8, the sample size needed is 45. The primary endpoint of surgical time will be initially assessed for each individual patient by determining the difference between the half of the laparoscopic hysterectomy procedure performed with the disposable device, specifically the Ligasure (Covidien) and the half of the laparoscopic hysterectomy procedure performed with the two reusable devices (Robi Bipolar and Storz laparoscopic shears) and determining if the mean difference score summed across all patients differs significantly from zero. Subsequent analyses will examine surgical times for attending physicians and residents separately where those using the disposable device are compared to those using the two reusable devices with independent students t test or the Kolmogorov-Smirnov test depending on the normality of the distributions. Parallel analyses will be performed for the secondary endpoint of estimated blood loss. Secondary endpoints of organ damage and other categorical intraoperative complications will be compared between the disposable and reusable device groups using chi-square and Fisher's Exact test.

Interventions

DEVICEdisposable device (Ligasure, Covidien)

One side of the uterine attachments would be transected using the disposable device (Ligasure, Covidien). . We will randomize the side for each energy source used on each side for every case. The number of sides performed by the attending surgeon will equal that of the less experienced resident surgeon.

DEVICEReusable device

One side of the uterine attachments would be transected using the reusable Robi bipolar and Storz laparoscopic

Sponsors

St. Louis University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
21 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Age 21 to 80 years of age * Scheduled for laparoscopic hysterectomy (prospectively)

Exclusion criteria

* Under 21 years of age * Known or anticipated malignancy

Design outcomes

Primary

MeasureTime frameDescription
The Primary Endpoint of This Study is Time Difference Between Cauterizing One Side of the Uterine Attachments, From the Round Ligament to the Uterine Artery on One Side, to the Time Detaching the Same Tissues on the Other SidePrimary outcome study data is collected with the first incision and completed with skin closure at the completion of the surgery.duration of surgery

Countries

United States

Participant flow

Participants by arm

ArmCount
Disposable Device Left and Resusable Devices Right
27 women were randomized to receive disposable device left and resusable devices right
24
Disposable Device Right and Reusable Devices Left
25 women were randomized to receive disposable device right and reusable devices left
21
Total45

Baseline characteristics

CharacteristicDisposable Device Right and Reusable Devices LeftDisposable Device Left and Resusable Devices RightTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
21 Participants24 Participants45 Participants
Age, Continuous39 years39 years39 years
Region of Enrollment
United States
21 participants24 participants45 participants
Sex: Female, Male
Female
21 Participants24 Participants45 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 45
serious
Total, serious adverse events
0 / 45

Outcome results

Primary

The Primary Endpoint of This Study is Time Difference Between Cauterizing One Side of the Uterine Attachments, From the Round Ligament to the Uterine Artery on One Side, to the Time Detaching the Same Tissues on the Other Side

duration of surgery

Time frame: Primary outcome study data is collected with the first incision and completed with skin closure at the completion of the surgery.

Population: Uterine Vessel Desiccation and Electrosurgical Cutting Time (min)

ArmMeasureValue (MEDIAN)
DisposableThe Primary Endpoint of This Study is Time Difference Between Cauterizing One Side of the Uterine Attachments, From the Round Ligament to the Uterine Artery on One Side, to the Time Detaching the Same Tissues on the Other Side8.4 minutes
ReusableThe Primary Endpoint of This Study is Time Difference Between Cauterizing One Side of the Uterine Attachments, From the Round Ligament to the Uterine Artery on One Side, to the Time Detaching the Same Tissues on the Other Side14.6 minutes
Comparison: The data will be analyzed using linear regression, Kolmogorov-Smirnov test, and chi-square analysis.p-value: <0.001Wilcoxon (Mann-Whitney)

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026